Member Info for ForFXSake

If they didn't have to pay anything on exercising the option then what is the point of that deadline? You just exercise then deliberate as long as you want. If you get to the point where you don't like it then just walk away.

Poor management if that's how it is allowed to work!

Interesting theory Soup. It does feel like something odd is going on with Oxilio. I thought Yaxley had links to Blackwell though.

I could never work out who was in which camp when it came to the board split. It kind of felt that Blackwell and DT were in opposite corners but I couldn't work where DG's or JH's allegiances were, especially as DG left following DT's departure. Then again, that was thrown into flux when, after assuming control, Blackwell threw the towel in too.

I did wonder if DG's move to freelance consultancy (that you mentioned yesterday) was linked at all to JH's decision to go freelance too. I'm half expecting them to both rock up on the same project again and have a nagging feeling that it could be at Ebers with DT again. That would definitely point to Ebers having designs on our IP.

I had to laugh at this though:

"..which coincidentally today has been pushed back further due to Ebers not filing their accounts for the past two years."

Who'd have figured?

There is no certainty about the company. That's why the price is where it is. That won't change until Anne does something to change it.

Yep. 1m shares is about £21k...well within the range of your common & garden twitter pump and dumper.

18m would be something to get excited about...just don't hold your breath for the TR1 :0)

Where did you find out about Gooding, Soup?

He's still down as a strategic advisor at Qureight on LinkedIn

Interesting, I didn't know that Soup. So he's parted ways with Muhunthan Thillai.

It's worth checking these people's profiles from time to time to see where they go.

So both he and Jo are now freelancers. I wonder if their paths will cross again somewhere in the near future?

My optimism for the Oxilio deal is waning fast. Unless they come back with a substantial revision to terms then I don't understand why it's taking so long.

I don't want a bad deal here but I think it's really important to make sure we have enough money to see us through to completion of the priority work on NXP002. That said, if they are taking the p*** then we should just walk away and draw a line under it. A worse than expected deal with Oxilio will make negotiations for NXP002 much more difficult if partners feel that we'll buckle under pressure.

I also don't understand why we can find a partner for NXP001 (CINV) if it is phase1 ready. If we can't find a partner for NXP001 then who is to say it will be any easier for NXP002?

Regarding TR1's, some question marks do remain. DG has never updated since the placing which makes me wonder if he's been quietly doing some dirty offloading like the others. We also never found out what that suspected buy was. Maybe it was a sell related to one of the other main dumpers after all.

If Oxilio crashes out then we have a long wait for anything and there is also the question mark about whether we have the cash to do it. I hope this doesn't end up being another one those shares that's kept afloat by endless placings.

Thanks for the info Soup.

For most shares, that kind of document would probably have a positive impact on the sp. Not here though.

Now why would they get turned down for a grant that would assist research into a potential treatment for something as damaging as Covid or long Covid?

It doesn't make sense if there is any chance that it could be effective.

They'd have prioritised it if there was any whiff of it having an impact.

..now reported in the UK from various press and TV media today.

https://mol.im/a/9717715

Shame nothing materialised from Blackwell's early rumblings on the possibility of NXP002 being a potential treatment for the lung inflammation symptoms.

I think it was in phase 2. Possibly why it's worth more

Thanks Soup.

Hopefully, one day, big pharma might take an interest in these comparisons. Not sure whether it's just poor self-projection on NFX's part or some other reason but we seem to be struggling to get any nibbles.

I can't imagine that it's simply because IPF isn't a big enough market for them though.

Well look on the bright side Cuddo, when it comes to being underwater, you're probably just snorkeling compared to many of us here.

I think his enthusiasm may have waned a little since the MM's dropped the bid from 2.35p to 2.1p this afternoon.

LoL

He's probably just waiting for the next giveaway placing to come round

Perhaps, but how far do you go with that before you realise there is no compromise? They've had 3 months to finalise an agreement.

News is the key, everything else is just P&D

I thinks it's the time it's taking to finalise that is spooking me now.

It's beginning to take on that very NFX historical trait of "it ain't happening but we ain't telling you", just like the Asian negotiations and the touted UK innovate grant.

The fact that it originated under the watch of the old board only adds to the feeling that it has a diminishing likelihood of coming to fruition with the passage of time.

I was really hoping Anne could at least bag something from Oxilio. It would send a positive message to any larger partners that might be out there to say that we do actually have products that are worth the risk of taking forward.

"Maybe that was the guy who had been charting NFX for ages and could see the opportunity for a £200 gain...."

I have to ask why would an 'accomplished' chartist choose a share with probably one of the most beautiful downtrends on the 3 year chart, to bag £200 going long?

If he was shorting at this level (if that's even possible) then he's more insane.